Sotio is dedicated to connecting patients and science
Since 2010, Sotio has been building a diverse biotechnology portfolio through in-house R&D, collaborations, and strategic investments. The company focuses on immuno-oncology and pioneering innovative cancer treatments. Based in Basel-Stadt, Sotio is advancing multiple projects across Phase I to III clinical trials, as well as in preclinical development.
After evaluating several European locations, the Basel Area emerged as the most advantageous choice for Sotio, thanks in large part to its extensive talent pool, an important factor for the company. The Basel Area Business & Innovation team provided valuable support throughout the settlement process.
The region has a large talent pool, which is an important criterion for us. The business environment is very friendly. The international community and the proximity to Germany and France are a big plus.
